Full Breakdown
Breakthrough Pancreatic Cancer Combo Shows 92% Response in Early Trial
6/9/2026, 1:50:32 PM
Core Trial Findings
An early-stage Phase 1/2 trial tested Tango Therapeutics’ PRMT5 inhibitor vopimetostat with Revolution Medicines’ KRAS-G12C inhibitor daraxonrasib in advanced MTAP-deleted, RAS-mutant metastatic pancreatic ductal adenocarcinoma (PDAC). Among 12 patients with 14-week follow-up, 11 (92 %) achieved an objective response, nine were confirmed, disease control was 100 %, and six-month progression-free survival reached 90 %. A parallel NSCLC cohort of three patients showed a 100 % response rate.
Background & Context
Pancreatic ductal adenocarcinoma has a five-year survival of roughly 13 %, leaving few effective options. Daraxonrasib monotherapy previously doubled median overall survival to 13.2 months versus chemotherapy. Vopimetostat targets PRMT5, an emerging oncology pathway. The drugs are co-developed by Tango Therapeutics, led by CEO Malte Peters, and Revolution Medicines.
Data & Statistics
Key outcomes: PDAC cohort (n=12) showed 92 % ORR (11 responders), nine confirmed, 100 % disease control, and 90 % six-month PFS. No patient discontinued treatment; no grade 4/5 adverse events occurred. NSCLC cohort (n=3) achieved 100 % ORR. An alternate vopimetostat + zoldonrasib arm reported 52 % ORR (14/27) and 74 % PFS. Daraxonrasib was dosed at 100 mg daily, lower than its 300 mg monotherapy dose and the 200 mg dose used with chemotherapy.
Why It Matters
The response magnitude could shift the therapeutic landscape for a disease with limited options. Tango’s shares jumped 43 % to $28.94; Revolution’s rose modestly. Analysts argue the data create a strong case for accelerated FDA approval, pending confirmatory trials.
Official Statements & Responses
Tango CEO Malte Peters said the trial “dramatically exceeded our expectations.” Leerink Partners called the activity “unprecedented” and highlighted a “strong synergy” between the agents, adding that regulators would be “hard-pressed to deny” approval.
Criticism & Opposition
Analysts caution that the dataset is small and follow-up short, limiting confidence in durability. The NSCLC arm includes only three patients. The reduced daraxonrasib dose (100 mg) raises questions about possible drug interactions or overlapping toxicities.
Conflicting Reports & Gaps
The trial reports a 92 % ORR with daraxonrasib but a 52 % ORR with the alternative zoldonrasib combination, without explanation for the discrepancy. Overall survival data and longer follow-up beyond 14 weeks are not provided.
Verbatim Quotes
- “WOW!” — Leerink Partners
- “The results from our ongoing combination trial dramatically exceeded our expectations,” — Malte Peters, CEO, Tango Therapeutics
- “The efficacy results speak for themselves,” — Leerink Partners analysts
- “Given the unprecedented activity seen in PDAC, a terminal disease with limited treatment options, we think the FDA would be hard-pressed to deny such a request,” — Leerink Partners analysts
What’s Next
Tango and Revolution will launch a registrational Phase 3 trial of vopimetostat + daraxonrasib in first-line MTAP-deleted PDAC, with potential second-line expansion pending regulatory feedback. Ongoing safety monitoring and longer-term efficacy assessments will guide further development.
